| Abstrakt: |
Chimeric antigen receptor gene-modified T (CAR-T) cell immunotherapy is considered as one of the most promising tumor treatments. The number of effector CAR-T cells is a key factor in determining the therapeutic effect of CAR-T cell therapy. The expansion of CAR-T cells in vitro is time and energy-consuming. After transfusion, it's difficult for CAR-T cells to infiltrate into solid tumors, resulting in a significant decrease in the number of CAR-T cells that can effectively inhibit solid tumors. Currently, the amplification of CAR-T cells has problems in enhancing amplification specificity and treatment safety, which hinders the clinical transformation of CAR-T cell therapy. In recent years, achievements in new immunity agonist and their downstream signals have provided more options for CAR-T amplification, and the novel administration methods of immunity agonist have further improved the safety of CAR-T amplification in vivo. This review analyzes the current challenges in CAR-T cell amplification, and systematically expounds the new strategies of CAR-T cell amplification in vitro and in vivo in recent years, providing new thoughts for the efficacy and capacity optimization of CAR-T cell therapy. [ABSTRACT FROM AUTHOR] |
